0000000000348748
AUTHOR
Maria-teresa Cedena
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
[Purpose] Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG).
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
On behalf of the PETHEMA/GEM Cooperative Group.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
PETHEMA/GEM Cooperative Group.
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma
Abstract Purpose: Undetectable measurable residual disease (MRD) is a surrogate of prolonged survival in multiple myeloma. Thus, treatment individualization based on the probability of a patient achieving undetectable MRD with a singular regimen could represent a new concept toward personalized treatment, with fast assessment of its success. This has never been investigated; therefore, we sought to define a machine learning model to predict undetectable MRD at the onset of multiple myeloma. Experimental Design: This study included 487 newly diagnosed patients with multiple myeloma. The training (n = 152) and internal validation cohorts (n = 149) consisted of 301 transplant-eligible patients…
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Key Points FlowCT is a new computational workspace for unveiling cellular diversity and objectively identifying biomarkers in large immune monitoring studies.FlowCT identified T-cell biomarkers predictive of malignant transformation and survival in SMM and active MM data sets.